Dr. Diego Andres Adrianzen Herrera, MD

Dr. Adrianzen Herrera practices at University of Vermont Medical Center in Burlington, Vermont, part of University of Vermont Health Network.

Dr. Adrianzen Herrera's NPI, 1114367463, was assigned on July 1, 2013. Dr. Adrianzen Herrera holds Vermont license 042-0014213.

Dr. Adrianzen Herrera's primary practice is University of Vermont Medical Center, at 111 Colchester Ave, Burlington, VT 05401 in Chittenden County. The practice phone is (802) 847-0000.

Dr. Adrianzen Herrera's primary practice is University of Vermont Medical Center in Burlington, Vermont, part of University of Vermont Health Network. Dr. Adrianzen Herrera is also affiliated with Champlain Valley Physicians Hospital. The medical group on file is University of Vermont Medical Center. Dmand AI also links Dr. Adrianzen Herrera to 3 more hospitals and 1 dialysis center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Adrianzen Herrera practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Adrianzen Herrera's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Adrianzen Herrera is licensed in Vermont.

CMS data shows 544 Medicare services from Dr. Adrianzen Herrera across 7 procedure codes in 2024, for 183 Medicare patients. Medicare paid $43,254 for them.

CMS counts 183 Medicare patients who saw Dr. Adrianzen Herrera in 2024. The largest group is 65 to 74, with 72 patients. 74% of them have high blood pressure, and 66% have high cholesterol. 15% are also on Medicaid. Their average risk score is 2.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Adrianzen Herrera's median patient age at 74, with 46% women.

In 2024, Dr. Adrianzen Herrera wrote 909 Medicare Part D claims for 90 patients. 79% of them were for generic drugs. CMS names the drug for 653 of them, across 18 drugs with 11 or more claims each, at $856,559 in total drug cost. In 2023, CMS named 748 claims across 23 drugs.

Dr. Adrianzen Herrera accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Adrianzen Herrera as offering telehealth.

Dmand AI links 12 papers to Dr. Adrianzen Herrera, published from 2017 to 2020. 2019 was the busiest year, with 5. The most frequent topics are Lung Neoplasms, Antineoplastic Agents and Carcinoma, Non-Small-Cell Lung. Dr. Adrianzen Herrera has published most often in Leuk Lymphoma. Dr. Adrianzen Herrera's most frequent co-authors are Ira J. Braunschweig, MD, Murali Janakiram, MD and Olga Derman, MD.

CMS Open Payments shows 3 general payments to Dr. Adrianzen Herrera from 2 drug and device companies from 2016 to 2019. Education make up the largest share, 78% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $114.